The cannabis sector ended March 2026 with another month of broad-based losses, deepening a year-to-date decline that has now left some benchmark instruments down nearly a quarter of their value since January. The AdvisorShares Pure U.S. Cannabis ETF (MSOS) fell 8.5% for the month and sits at roughly -25% year-to-date; the Amplify Alternative Harvest ETF (MJ) shed 11.3%. Neither geography nor business model offered much shelter - U.S. multi-state operators, Canadian licensed producers, and adjacent Tier 2 businesses all moved lower, a synchrony that points to something systemic rather than idiosyncratic.
Macro Pressure Meets a Sector Already Running on Fumes
Cannabis equities have never been easy to own. The asset class has carried extreme volatility, thin liquidity, and binary regulatory risk since the first wave of public listings in the late 2010s. What March 2026 added to that mix was a deteriorating macroeconomic backdrop that would have hurt almost anything speculative - and cannabis, fairly or not, still occupies the speculative end of the market.
The S&P 500 itself declined 4.9% during the month, buffeted by geopolitical tensions concentrated around the Middle East and the attendant energy market anxiety. When roughly 20% of global oil supply sits in potential jeopardy - specifically, fears around restricted passage through the Strait of Hormuz - capital tends to flee risk assets in a hurry. Energy stocks gained; almost everything else didn't. Cannabis, with no natural hedge against oil shocks and no institutional ownership base to absorb selling pressure, bore the brunt of the rotation disproportionately.
There is a pattern here worth naming. Markets have faced comparably disorienting macro shocks before - 1987, 2001, 2008 - and each time, the sectors least anchored by fundamental investor conviction get hit hardest. Cannabis equities, still largely excluded from institutional portfolios on compliance grounds alone, are effectively priced at the margin by retail investors and specialist funds. When those participants get nervous, there is no deep-pocketed buyer waiting on the other side.
The Numbers: Wide Dispersion, Mostly Down
Within the Tier 1 CRB universe - the largest pure-play cannabis operators tracked by CRB Monitor - the equally-weighted basket returned -7.7% for March. The losses were distributed unevenly but were hard to avoid entirely. On the MSO side, Trulieve Cannabis Corp. (CSE: TRUL) fell 12.2%, Cresco Labs Inc. (CSE: CL) dropped 10.3%, and Curaleaf Holdings (CSE: CURA) gave back 6.0%. Green Thumb Industries (CSE: GTII) and Verano Holdings (CSE: VRNO) held up relatively better, losing less than 1% each - modest outperformance, though in absolute terms still negative.
Canadian names fared worse in several cases. Tilray Brands (Nasdaq: TLRY) declined 18.0%, Canopy Growth (TSX: WEED) lost 14.6%, and SNDL (Nasdaq: SNDL) shed 11.7%. High Tide (TSXV: HITI) and Cronos Group (TSX: CRON) posted losses of 9.5% and 5.6%, respectively. The American Cannabis Operator Index finished the month down 5.5%.
The Tier 2 basket - companies that touch the cannabis industry indirectly through ancillary products and services - held up better, declining 1.2% against the Tier 1 basket's 7.7% loss. That gap is not unusual in the short term; Tier 2 CRBs draw revenue from the cannabis ecosystem but are insulated from the most acute regulatory and balance sheet risks that dog plant-touching operators. Historically, though, correlation between the two groups runs high over longer periods, which suggests the current spread tends to compress. If that dynamic holds, it could support a tactical case for Tier 2 names - though "tactical" in this sector has a habit of meaning longer than expected.
One notable outlier: a legacy cannabis-adjacent company surged more than 900% after announcing a strategic pivot. That kind of extreme move is catnip for financial headlines, but it tells you more about the speculative character of the space than about any underlying improvement in conditions. One stock defying gravity doesn't change the sector's center of gravity.
The Fundamental Disconnect That Won't Close
Here's the catch - and it is a genuine one. The operational picture for parts of the industry is not actually deteriorating. Select companies reported continued revenue growth in the period, with international cannabis sales rising and margins expanding in certain segments. Long-term demand expectations remain structurally intact. Consumer interest in cannabis products has not reversed. The global market continues to expand, particularly in European jurisdictions moving toward liberalization.
And yet equity performance and operational performance remain stubbornly disconnected. The reason is not complicated: equity markets price near-term catalysts, and for U.S. cannabis operators, the one catalyst that matters most - federal rescheduling or legislative reform - has been deferred so many times that most investors have stopped building it into their base case. The American Cannabis Operator Index has spent the better part of five years waiting for Washington, and Washington has delivered almost nothing. That history has a cost; investor optimism is a depletable resource.
Balance sheet fragility compounds the problem. Many of the largest U.S. operators carry significant debt loads incurred during the expansion phase of 2019-2022, at a time when capital was cheap and federal reform seemed imminent. Servicing that debt under Section 280E of the Internal Revenue Code - which denies standard business deductions to cannabis companies - remains extraordinarily punishing. Even companies posting top-line growth can find themselves cash-constrained in ways that make equity holders, quite rationally, nervous.
Micro-Caps in All but Name, and What That Means for the Sector
Perhaps the most structurally significant development of the past several years is one that rarely gets stated plainly: essentially every publicly traded cannabis company has now shrunk to micro-cap status. Some have lost more than 90% of their peak market capitalization. The practical consequence is that the vast majority of institutional investors - pension funds, endowments, large asset managers - are prohibited from owning them by internal policy, regardless of their views on the underlying business.
That creates a feedback loop with no obvious exit. Without institutional ownership, liquidity stays thin. Thin liquidity amplifies volatility. High volatility deters institutional ownership. The sector is effectively stuck in a structural exile from the capital it would need to stabilize, invest, and grow out of its current difficulties. Federal reform would break that loop - access to banking, relief from 280E, and eventual uplisting to major exchanges would all attract institutional capital. But as March 2026 demonstrated once again, that reform remains stubbornly prospective.
For investors still in the space, the operational improvements are real and worth watching. The equity story, for now, is mostly about waiting - and managing the cost of that wait.
